TY - JOUR
T1 - Corneal Endothelial Transplantation in Uveitis
T2 - Incidence and Risk Factors
AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group
AU - Roldan, Ana M.
AU - Zebardast, Nazlee
AU - Pistilli, Maxwell
AU - Khachatryan, Naira
AU - Payal, Abhishek
AU - Begum, Hosne
AU - Artornsombudh, Pichaporn
AU - Pujari, Siddharth S.
AU - Rosenbaum, James T.
AU - Sen, H. Nida
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Bhatt, Nirali P.
AU - Foster, C. Stephen
AU - Jabs, Douglas A.
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Buchanich, Jeanine M.
AU - Kempen, John H.
N1 - Funding Information:
Funding/Support: Support was received from National Institute of Health National Eye Institute grants EY014943 and R21EY026717, Mass Eye and Ear Global Surgery Program, and Sight for Souls. Jennifer E. Thorne receives financial support from National Institutes of Health, National Eye Institute.
Funding Information:
Acknowledgment: Drs Roldan and Zebardast served jointly as co-first authors. Robert B. Nussenblatt is deceased. Funding/Support: Support was received from National Institute of Health National Eye Institute grants EY014943 and R21EY026717, Mass Eye and Ear Global Surgery Program, and Sight for Souls. Jennifer E. Thorne receives financial support from National Institutes of Health, National Eye Institute. Financial Disclosures: James T. Rosenbaum is a consultant for AbbVie, Gilead, Santen, Horizon, Janssen, Eyevensys, Novartis, Roche, and Corvus, receives financial support from Pfizer, Alcon Research Institute, Janssen, and Sun Pharma, and receives royalties from UpToDate. Grace A. Levy-Clarke is a consultant for AbbVie, Mallinckrodt, and Sanofi Genzyme, receives financial support from Allergan, Mallinckrodt, and Sanofi Genzyme, and is a lecturer for AbbVie and Sanofi. Eric B. Suhler is a consultant for EyeGate, Santen, AbbVie, Clearside, EyePoint, and Gilead, and receives financial support from EyeGate, AbbVie, Clearside, EyePoint, Bristol Myers Squibb, Genentech, Gilead, and EyeGate. Jennifer E. Thorne is a consultant for AbbVie and Gilead, is a scientific advisory board member for AbbVie and Clearside, receives financial support from Allergan and Santen, and receives royalties from UpToDate. C. Stephen Foster is a consultant for Aldeyra, Allakos, Bausch & Lomb, Eyegate, Genentech, Novartis, and pSivida, receives financial support from Aldeyra, Bausch & Lomb, Eyegate, Novartis, pSivida, Aciont, Alcon, Clearside, Dompé, and Mallinckrodt, is a lecturer for Alcon, Mallinckrodt, and Allergan, and is an equity owner in Eyegate. John H. Kempen is a consultant for Gilead and an equity owner in Betaliq. The other authors indicate no financial support or conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/4
Y1 - 2022/4
N2 - PURPOSE: To estimate the incidence of corneal endothelial transplantation (CET) and identify risk factors among patients with noninfectious ocular inflammation. DESIGN: Retrospective cohort study. METHODS: Adult patients attending United States tertiary uveitis care facilities diagnosed with noninfectious ocular inflammation were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Time-to-event analysis was used to estimate the incidence of CET, including penetrating keratoplasty, Descemet stripping endothelial keratoplasty, or Descemet membrane endothelial keratoplasty procedures. The incidence of CET was calculated. Potential risk factors for CET were also evaluated using Cox regression, accounting for correlation between eyes of the same patient. RESULTS: Overall, 14,264 eyes met eligibility criteria for this analysis, with a median follow-up of 1.8 eye-years. The Kaplan-Meier estimated incidence of CET within 10 years was 1.10% (95% CI, 0.68%-1.53%). Risk factors for CET included age >60 years vs <40 years (adjusted hazard ratio [aHR], 16.5; 95% CI, 4.70-57.9), anterior uveitis and scleritis vs other types (aHR, 2.97; 95% CI, 1.46-6.05; and aHR, 4.14; 95% CI,1.28-13.4, respectively), topical corticosteroid treatment (aHR, 2.84; 95% CI, 1.32-6.13), cataract surgery (aHR, 4.44; 95% CI, 1.73-11.4), tube shunt surgery (aHR, 11.9; 95% CI, 5.30-26.8), band keratopathy (aHR, 5.12; 95% CI, 2.34-11.2), and hypotony (aHR, 7.38; 95% CI, 3.14-17.4). Duration of uveitis, trabeculectomy, peripheral anterior synechia, and ocular hypertension had no significant association after multivariate adjustment. CONCLUSIONS: In patients with ocular inflammation, CET occurred infrequently. Tube shunt surgery, hypotony, band keratopathy, cataract surgery, and anterior segment inflammation were associated with increased risk of undergoing CET; these factors likely are associated with endothelial cell damage.
AB - PURPOSE: To estimate the incidence of corneal endothelial transplantation (CET) and identify risk factors among patients with noninfectious ocular inflammation. DESIGN: Retrospective cohort study. METHODS: Adult patients attending United States tertiary uveitis care facilities diagnosed with noninfectious ocular inflammation were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Time-to-event analysis was used to estimate the incidence of CET, including penetrating keratoplasty, Descemet stripping endothelial keratoplasty, or Descemet membrane endothelial keratoplasty procedures. The incidence of CET was calculated. Potential risk factors for CET were also evaluated using Cox regression, accounting for correlation between eyes of the same patient. RESULTS: Overall, 14,264 eyes met eligibility criteria for this analysis, with a median follow-up of 1.8 eye-years. The Kaplan-Meier estimated incidence of CET within 10 years was 1.10% (95% CI, 0.68%-1.53%). Risk factors for CET included age >60 years vs <40 years (adjusted hazard ratio [aHR], 16.5; 95% CI, 4.70-57.9), anterior uveitis and scleritis vs other types (aHR, 2.97; 95% CI, 1.46-6.05; and aHR, 4.14; 95% CI,1.28-13.4, respectively), topical corticosteroid treatment (aHR, 2.84; 95% CI, 1.32-6.13), cataract surgery (aHR, 4.44; 95% CI, 1.73-11.4), tube shunt surgery (aHR, 11.9; 95% CI, 5.30-26.8), band keratopathy (aHR, 5.12; 95% CI, 2.34-11.2), and hypotony (aHR, 7.38; 95% CI, 3.14-17.4). Duration of uveitis, trabeculectomy, peripheral anterior synechia, and ocular hypertension had no significant association after multivariate adjustment. CONCLUSIONS: In patients with ocular inflammation, CET occurred infrequently. Tube shunt surgery, hypotony, band keratopathy, cataract surgery, and anterior segment inflammation were associated with increased risk of undergoing CET; these factors likely are associated with endothelial cell damage.
UR - http://www.scopus.com/inward/record.url?scp=85122477160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122477160&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2021.10.031
DO - 10.1016/j.ajo.2021.10.031
M3 - Article
C2 - 34780793
AN - SCOPUS:85122477160
SN - 0002-9394
VL - 236
SP - 288
EP - 297
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -